2014 Market Research: January 2015

Friday 30 January 2015

China Orthopedic Instrument Industry Report, 2014-2017 - Research Background & Research Ideas

“The Report China Orthopedic Instrument Industry Report, 2014-2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz”

Benefiting from accelerated aging population and rising proportion of reimbursement for medical expenses, the Chinese orthopedic instrument market demand has been effectively released, with its scale presenting a CAGR of 19.2% during 2009-2013. Trauma products, spine products and joint products are three product segments of orthopedic instruments in China, of which trauma products holding the bulk with 36.9% market share in 2013.

View Full Report at http://www.marketresearchreports.biz/analysis/218800

Being optimistic about bright future of China orthopedic instrument industry, some foreign and domestic companies are speeding up their layout in orthopedic instrument market though mergers and acquisitions. In 2012, Medtronic, Inc. acquired the most competitive orthopedic device maker in China-- China Kanghui Holdings for USD 816 million; In Jan. 2013, Stryker Corporation bought China’s largest trauma product makers-- Trauson Holdings Company Limited for HKD5.9 billion; In Sep. 2011, MicroPort Scientific Corporation entered orthopedic instrument market by purchasing Suzhou Best at transaction value of RMB 110 million, and acquired Wright's OrthoRecon business at USD 290 million in Jan. 2014.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/218800

The Chinese orthopedic instrument market now is dominated by Johnson & Johnson, Zimmer, Medtronic, Stryker and other foreign companies, together holding 40%-50% market share. However, local Chinese companies like Shandong Weigao Group Medical Polymer Co. Limited, Shanghai Kinetic Medical Co., Ltd. and United Orthopedic Corporation have made some progress in R&D and production technology in recent years, and grabbed some marker share by virtue of advantages in cost and channel.

Shandong Weigao Group Medical Polymer has become the largest local orthopedics company in China with a market share of 4.3%; Shanghai Kinetic Medical is a leader in vertebroplasty interventional operation system, occupying about 50% of the Chinese percutaneous kyphoplasty (PKP) market; United Orthopedic Corporation is a champion in artificial knee/hip joint with 4%-6% market share in China.

Table of Content

1. Overview of Orthopedic Instrument Industry

1.1 Definition

1.2 Classification

1.3 Industry Chain

2. Development of Global Orthopedic Instrument Industry

2.1 Overview

2.2 Forecast

3. Development of China Orthopedic Instrument Industry

3.1 Overview

3.2 Market Structure

3.3 Import and Export

3.3.1 Import

3.3.2 Export

3.4 Competitive Landscape

3.5 Barriers to Entry

3.5.1 Technology Barrier

3.5.2 Market Access Barrier

3.5.3 Sales Channel Barrier

3.5.4 Talent Barrier

3.6 Sales Model

Related Reports

Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability

GBI Research’s new report, “Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability” provides key data, information and analysis on the orthopedic devices market in China, India and Brazil. The report provides market landscape, competitive landscape and market trends information the orthopedic devices market.

The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings.

Pioneer Surgical Technology, Inc. Market Share Analysis

GlobalDatas new report, Pioneer Surgical Technology, Inc. Market Share Analysis provides in-depth information on Pioneer Surgical Technology, Inc.s market position in the different medical equipment markets it operates in. The report provides Pioneer Surgical Technology, Inc. market share information in one key market category Spinal surgery. The report also provides data and information on the overall competitive landscape of the markets, the company operates in. The report is supplemented with global corporate-level profile with information on the companys business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.

About Us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

Contact Us

Office: State Tower

90 Sate Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Thursday 29 January 2015

China Passenger Car Telematics Industry Report, 2014-2017 - Opportunities and Operator Business Models

Since GM OnStar and Toyota G-Book officially embarked on China’s market in 2009, Chinese passenger car brands have launched their own Telematics products, such as Ford SYNC, Nissan CARWINGS, SAIC InKaNet, Honda HondaLink, Geely G-NetLink, Mercedes-Benz CONNECT, Volvo Sensus, BMW ConnectedDrive, Yueda KIA UVO, Dongfeng Citroen Citro?n Connect, Dongfeng Peugeot Blue-i, Hyundai Blue Link, Changan in Call, Chery Cloudrive and so on.

In order to occupy "the fourth screen" in the mobile Internet era, domestic and foreign Internet giants begin to highlight Internet of Vehicles (IoV) in 2014, for example, Apple has released CarPlay vehicle system, Google has launched Android Auto, Alibaba has acquired AutoNavi and cooperated with SAIC to develop Internet automotive supplies, Tencent unveiled Lubao Box and held stake in Navinfo, Baidu collaborated with TimaNetworks to launch CARNET. As China's position in the global automotive market becomes more important, the competition in the Chinese passenger car Telematics market will turn to be more intense.

View Full Report at http://www.marketresearchreports.biz/analysis/226027

Chinese Telematics market falls into OEM market and aftermarket. The traditional OEM market focuses on traffic safety, such as remote assistance and other functions; the aftermarket emphasizes entertainment and other personalized services. However, OEM brands have paid more attention to the combination with mobile Internet and hope to make users have better experience; coupled with their inherent advantages in the industrial chain, they expect to master higher market share in the future.

There were more than 4,000 enterprises engaged in IoV aftermarket in China around 2012, but most of them have closed down or been struggling to survive now. For now, even large suppliers (like PATEO and Chinatsp) linked with considerable automobile companies see unsatisfying profitability. The fundamental reason lies in the lack of eye-catching Telematics applications which users are eager to pay for. Navigation and radio of the traditional vehicle system are the most frequently used functions for users. Telematics vendors intend to introduce a variety of innovative applications to intensify user viscosity, but they see little effect, which directly makes the IoV activation rate of new cars remain at less than 30%.

In the Chinese passenger car IoV market, GM OnStar has always played a leading role. In the first eight months of 2014, about 77,000 Chinese users pre-installed OnStar for the first time, and the majority of them were Buick owners.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/226027

Currently, the second-ranked passenger car IoV brand is Ford SYNC. In August 2014, Ford SYNC attracted about 48,000 new users in China.

In the future, Telematics should not only function as a marketing tool for automobile enterprises to enhance sales volume, but also a product that users really need. In order to stimulate consumption, all manufacturers need to accelerate the integration of automotive information devices and mobile Internet devices to provide users with diversified mobile Internet value-added services, as well as vigorously promote mobile mapping and connection with smart wearable devices to serve customers considerately.

With the participation of a large number of Internet companies and enriched IoV services, the activation rate of IoV features in the Chinese passenger car market is expected to keep rising, and the IoV user base will also expand rapidly.

Table of Content

1 Overview of IoV

1.1 Related Definitions

1.1.1 Intelligent Transportation System

1.1.2 IoV

1.1.3 Telematics

1.2 Industry Chain

2 China Telematics Market

2.1 Overview

2.2 Business of Main Telematics Brands

2.3 New Market Size

3 Telematics Business of Joint Ventures in China

3.1 Shanghai GM OnStar

3.1.1 Overview and Support

3.1.2 Business Analysis

3.1.3 Number of New Users

3.1.4 Development Strategy

3.2 Toyota G-BOOK

3.2.1 Overview and Support

3.2.2 Business Analysis

3.2.3 Number of New Users

3.2.4 Development Strategy

3.3 Honda HondaLink

Airbag fabric is mainly used to produce automotive airbag. Affected by technology, certification and supply chain relationship, there are higher barriers to entry for new manufacturers. Globally, the supply of airbag fabric is monopolized by the manufacturers from Japan, Europe and America. Similarly, the supply of airbag yarn (raw material for airbag fabric) is also in a state of oligopoly, basically controlled by American INVISTA, German PHP, Japanese Toray and several other companies.

Benefiting from a burgeoning automobile market in China, the demand for airbag increases rapidly, with domestic demand for airbag fabric reaching 28.94 million meters in 2013. As China introduces more and more laws and regulations about safety products, automotive airbag grows popular and installation rate rises gradually, the demand for airbag fabric in China will be huge, expected to stand at 43.86 million meters in 2018.

China End-of-Life Vehicle (ELV) and Dismantling Industry Report,2014-2017

China's automobile industry has ushered in an explosive growth since 2000, with car ownership rising to 137 million by 2013, second only to the United States. According to an estimated average car scrappage deadline of 10-15 years, China will see the first car scrappage peak in 2015.

China's overall automobile scrap rate was only 4% in 2013, far lower than 6%-8% of developed countries, mainly because national policies on motor vehicle liquidation are still unclear and the industry still desires to be regulated. At the same time, China’s low capacity to formally dismantle and process end-of-life vehicles (ELVs) is far behind the needs.

About Us

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

Contact Us

Office: State Tower

90 Sate Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Wednesday 28 January 2015

Global and China Photovoltaic Glass Industry Trends, Estimates And Forecast Report, 2014-2018

Featuring controllable light transmitting, energy-saving & generation and environmental friendliness, photovoltaic glass (PV glass) is primarily applied in solar cell module, and its transparency directly affects conversion efficiency of solar cell. PV glass consists mainly of crystalline silicon PV glass and thin-film PV glass.

PV glass is an important accessory in solar cell industry, growing along with development of PV industry. During 2000-2014, Global installed PV capacity recorded CAGR of 42.9%, compared with 70.7% in China.

View Full Report at http://www.marketresearchreports.biz/analysis/242587

Driven by PV industry, China’s PV glass consumption has increased gradually, exceeding 200 million m2 in 2014. Since 2006, promoted by big profits and favorable policies, various domestic manufacturers has invested to build PV glass production lines, combined with the shifting of foreign companies into China, thus leading to rapid expansion of PV glass capacity in China. Standard Conditions for the Photovoltaic Manufacturing Industry issued in 2015 lifted access threshold of PV industry, thus decelerating expansion pace of PV glass capacity.

With improvement in return on investment (ROI) in PV-related industries, foreign companies like AGC explore high-end PV glass business via cooperation; domestic flat glass manufacturers including CSG Holding and Xinyi Glass actively expand PV glass capacity; new entrants such as IRICO Electronics and China National Building Materials also make investment in PV glass field.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/242587

AGC: Established partnership with Rolith in 2013 to co-develop advanced anti-reflective glass; entered into a strategic cooperation agreement with Spanish Onyx Solar in 2014 to promote and sell PV glass within North America manufactured by Onyx Solar

CSG Holding: In Mar. 2014, Wujiang CSG ultra-white rolled solar glass production line was completed and put into operation, with capacity of 650t/d and costs down more than 30% than that of the first and second production lines; in Nov. of the same year, the company completed high-performance ultra-thin glass production line mainly for the production of touch screen and PV module cover plate.

Xinyi Glass: In Nov. 2014, the company spent HK$ 77.31 million to buy the land in Malacca, Malaysia for the construction of an ultra-clear glass production plant, with products targeting Thailand, the Philippines and Singapore.

IRICO Electronics: The company sold shares twice, totaling 10 million, and obtained RMB76.40 million for development of solar PV glass and new electronic chemical materials.

China National Building Materials: The company has, in recent years, set foot in ultra-clear PV glass, TCO glass, etc, and built dozens of ultra-clear PV glass. In Sep. 2014, Bengbu Design & Research Institute for Glass Industry of CNBM acquired Avancis under France Compagnie de Saint Gobain, which manufactures thin-film solar cell and CIGS thin film cell, to further promote thin film solar industry chain.

Table Of Contents

1. Overview of PV Glass

1.1 Definition and Classification

1.2 Application

1.3 Characteristics

1.4 Manufacturing Technology

2. Development Environment of PV Glass

2.1 Policy Environment

2.1.1 Japan

2.1.2 China

2.2 Industry Environment

3. Development of PV Glass Industry

3.1 Global

3.1.1 PV

3.1.2 PV Glass

3.2 China

3.2.1 PV

3.2.2 PV Glass

4. Main PV Glass Products

4.1 Super Clear Patterned Glass

4.1.1 Profile

4.1.2 Global Market Demand

4.1.3 Status Quo of Chinese Market

4.1.4 Competitive Landscape

4.2 TCO Glass

4.2.1 Profile

4.2.2 Global Market Demand

4.2.3 Status Quo of Chinese Market

4.2.4 Competitive Landscape

4.3 PV Anti-reflective Glass

Carbon fiber is the new-generation reinforced fiber, mainly used in the fields of aerospace, industry, sports and leisure. In 2014, the global industrial applications like natural gas, wind power and automobiles showed the largest demand for carbon fiber, 64% or so.

In 2014, the global carbon fiber capacity totaled approximately 130,000 tons, mainly contributed by Japan, Europe and the U.S.. The world's top five companies -- Toray, Teijin, Mitsubishi Rayon, Germany SGL and Formosa Plastics shared 60% of the global carbon fiber capacity together.

China Quartz Glass Material and Product Industry Report, 2015

The materials and products made of quartz glass are mainly used in a broad array of fields, including electric light source, semiconductor, optical communication, aerospace, and solar energy. Among them, solar energy constitutes the major consumption area for Chinese quartz glass materials and products, accounting for roughly 35% of the total revenue. That was followed by semiconductor and electric light source, which occupy 23% and 21%, respectively.

In 2001-2012, driven by the growth in China's electronic information industry, electric light source industry, and photovoltaic industry, the revenue from quartz glass material and product industry in China recorded a CAGR of about 24%. In 2013, the revenue from this industry reached RMB5.789 billion, up 8.90%, year on year. In 2014, it continued to grow at an annual growth of approximately 10%, a rate that was slightly lower than that prior to 2011, and this was mainly resulted from a downturn in downstream sectors, especially in the photovoltaic industry.

About Us

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

Contact Us

Office: State Tower

90 Sate Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Market Overview: Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics

“The Report Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz”

GBI Research, the leading business intelligence provider, has released its latest research: “Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics”, which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis.

View Full Report at http://www.marketresearchreports.biz/analysis/242389

The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020. The US had the largest market share in 2013, equivalent to a global share of 44.1%, followed by Japan and Germany with 14.7% and 11.9% respectively. Spain had the lowest market share of the leading eight at 4.1%. All markets covered in the report are expected to witness a slower growth rate than Japan, which will grow at a CAGR of 5%. However, this moderate growth will be stymied by the expected uptake of lower-priced biosimilar versions of bevacizumab and cetuximab due to the expiration of the patents of Avastin and Erbitux in the latter half of the forecast period. Also expected is the launch of generic versions of capecitabine, which will also affect the market. However, this will be offset by the launch of premium-priced emerging therapies. Stivarga is expected to be one of the biggest drivers of growth in the CRC market, primarily due to its expected line extension in the first-line metastatic setting as a maintenance treatment for patients with resected liver metastases. The launch of Lonsurf (TAS-102), approved in Japan in 2014, in the third- and fourth-line settings will further increase the pharmacological treatment rates in these lines, which will give patients a more tolerable alternative to Stivarga. The moderate uptake of other late-stage pipeline products, panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/242389

The CRC pipeline is highly robust, with potential drug candidates across various Phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. As well as these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

Scope

The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada. It includes:

A brief introduction to CRC, including the disease’s pathogenesis, etiology, diagnosis and treatment algorithms
In-depth analysis of currently marketed drugs for CRC, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy
A comprehensive review of the pipeline for CRC, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target
Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type
Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets
Discussion of the drivers of and barriers to market growth
In-depth analysis of all licensing and co-development deals that have occurred in the CRC market since 2006

Reasons To Buy

The report will enhance your decision-making capability by allowing you to:

Understand the CRC pipeline and the factors that indicate that it is becoming more innovative
Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be
Follow the trends in CRC clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates
Observe the potential growth patterns expected for the CRC market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country strategy through an understanding of key drivers and barriers in the CRC market
Accelerate and strengthen your market position by identifying key companies for strategic partnerships

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Colorectal Cancer

2.2 Symptoms

2.3 Epidemiology

2.4 Pathophysiology

2.4.1 Histology

2.4.2 Genetic Basis

2.4.3 Etiology of Colorectal Cancer

2.5 Diagnosis

2.5.1 Digital Rectal Examination

2.5.2 Fecal Occult Blood Test

2.5.3 Flexible Sigmoidoscopy

2.5.4 Colonoscopy

2.5.5 Virtual Colonoscopy

2.5.6 Double Contrast Barium Enema

2.6 Prognosis and Disease Staging

2.7 Treatment Options

2.7.1 Surgery and Radiation Therapy

2.7.2 Chemotherapy

2.7.3 Targeted Therapies

2.7.4 Resistance to Pharmacological Therapies

2.7.5 Treatment Guidelines

2.8 GBI Research Report Guidance

GBI Research, a leading business intelligence provider, has released its latest research report: “Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches”. The report provides estimates of the market size for 2013, along with forecasts until 2020 for the Asia-Pacific markets of India, China, Australia and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Ovarian Cancer (OC).

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-2019)

The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.

About Us

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

Contact Us

Office: State Tower

90 Sate Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Report Overview: Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches

“The Report Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Off-patent Chemo-regimens to Retain Dominance Despite New Launches provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz”

View Full Report at http://www.marketresearchreports.biz/analysis/242400

Platinum-based chemotherapy, predominantly the chemotherapy regimen paclitaxel and carboplatin, is the standard of care for the treatment of platinum-sensitive OC (both first-line and recurrent). The initial treatment is quite effective, with the majority of patients entering remission. However, almost all relapse, and after successive periods of remission and relapse either die or progress to platinum-resistant disease, for which the prognosis is poor. There is a clear gap in the market for maintenance therapies, as well as for more effective treatment options in platinum-resistant or refractory patients.

Although the current developmental pipeline is quite crowded, efficacy with these late-stage drugs has been poor, at best demonstrating minimal improvements in progression-free survival, but not overall survival. The promising investigational drug candidates olaparib and trebananib are expected to gain approval during the forecast period. However, even on approval they are not expected to have a high market penetration, owing to their minimal therapeutic efficacy and anticipated premium prices. As a result, the OC market in APAC is expected not be driven by new drug approvals, but primarily by inflation, and the increase in the prevalence of OC. Market revenue is forecast to rise at a limited CAGR of 5.1% to $417.6m in 2020.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/242400

Despite the poor clinical performance of current late-stage pipeline drugs, there is evidence of continued interest in the OC market, with a high number of drug candidates in the initial developmental pipeline, particularly at the Preclinical phase. There is a wide range of novel molecular targets distributed among these drug candidates, including growth factors, serine/threonine protein kinases and tumor associated antigens. This suggests a continued interest in introducing more targeted therapies into the treatment of OC, the use of which in this indication lags significantly behind that in others in oncology.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for OC. It covers and includes:

A brief introduction to OC, including the disease’s pathogenesis, risk factors and diagnosis
In-depth analysis of the drug combinations used in the treatment of OC, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
Multi-scenario forecast market data to 2020, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
Discussion of the drivers and barriers for market growth
In-depth analysis of licensing and co-development deals involving drugs indicated in OC, including an outline of the key deals

Reasons To Buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:

Understand the efficacy and safety of the current monotherapies and drug combinations used in the treatment of OC, with in-depth analysis of the disease treatment algorithm
Understand the key signaling pathways and molecular targets currently under investigation in OC drug development
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent
Observe the trends in clinical trial duration and size among clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for OC therapeutics
Assess the potential clinical and commercial impact of current late-stage pipeline molecules in the OC therapeutics market

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Disease Pathophysiology

2.1.1 Ovarian Cancer – A Group of Distinct Diseases

2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling Pathways

2.2 Symptoms and Diagnosis

2.3 Risk Factors

2.3.1 Age

2.3.2 Inherited Genetic Mutations

2.3.3 Greater Number of Lifetime Ovulations

2.3.4 Weight

2.3.5 Previous Medical Conditions

2.4 Treatment Algorithm

2.4.1 Surgery

2.4.2 First-Line Chemotherapy

2.4.3 Maintenance Therapy

2.5 Recurrent Disease

3 Marketed Products

3.1 Carboplatin

3.2 Paclitaxel

3.3 Gemcitabine

3.4 Topotecan

3.5 Pegylated Liposomal Doxorubicin

3.6 Yondelis

3.7 Avastin

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-2019)

Scope of the report

About Us

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

Contact Us

Office: State Tower

90 Sate Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Thursday 8 January 2015

Energy Harvesting/ Regeneration for Electric Vehicles Land, Water & Air 2015-2025 - Opportunities and Growth Drivers

“The Report Energy Harvesting/ Regeneration for Electric Vehicles Land, Water & Air 2015-2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz”

The electric vehicle industry - land, water and air - is rapidly rising to become a huge market of over $533 billion by 2025. Some run entirely on harvested energy as with solar lake boats. Others recycle energy as with regenerative braking of cars, buses and military vehicles harvesting kinetic energy. Others use different forms of harvesting either to charge the traction batteries or to drive autonomous devices as we progress to the wireless vehicle.

View Full Report at http://www.marketresearchreports.biz/analysis/235017

In some cases, harvesting is making completely new forms of electric vehicle possible such as "glider" Autonomous Underwater Vehicles (AUVs) that stay at sea for years and surface to gain electricity from both wave power and sunshine whenever necessary. Indeed, multiple forms of energy harvesting on one vehicle is becoming much more common from cars to superyachts. This report is the first to provide technical and marketing analysis of the rapidly growing market for energy harvesting in electric vehicles - land, water and air - with forecasts.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/235017

This report gives a wealth of examples of energy harvesting in action on electric vehicles by land, water and air. It summarises trends in diagrams, tables and text to make it easy to compare essential information. Forecasts for adoption in 2015 and 2025 are backed by ten year forecasts for electric vehicle sales by type, 2014-2024 by category - number, unit value and market value. A critical explanation of all the technologies is given with the good and bad aspects and assessment of likely future progress. The work of a large number of suppliers and adopters is assessed.

Table of Contents

1. EXECUTIVE SUMMARY AND CONCLUSIONS

1.1. What is energy harvesting?

1.2. Choices of harvesting

1.3. Opportunities for energy harvesting in cars

1.4. Market size of EV energy harvesting 2014-2025

1.5. Largest sectors

1.6. Regenerative braking

1.7. Large UK Government grants for KERS harvesting

1.8. Energy harvesting for racing cars shows the way

2. INTRODUCTION

2.1. Energy harvesting

2.1.1. Textron Bell helicopter sensing

2.1.2. Train brakes

2.1.3. MEMS

2.2. Electric vehicle

2.3. Needs

2.3.1. Range and cost

2.3.2. Hybrid vs pure electric

2.3.3. Biomimetics

2.4. Options and examples

2.4.1. ETH, QinetiQ solar plane

2.4.2. Amerigon thermoelectrics for cars, etc

2.4.3. Military land vehicles

2.4.4. NASA on Mars- planetary exploration vehicles

2.5. Bluecar

Global and China Automotive Connector Industry Report, 2014-2015

Global and China Automotive Connector Industry Report, 2014-2015 contains the followings:

Overview of Global and Chinese Automotive Market
Analysis on Automotive Connector Industry and Market
Research on 13 Major Automotive Connector Companies

As the most potential segment in the connector industry, automotive connectors will trigger the market value of USD12.7 billion (up 5.3% from 2013) in 2014, whilst the global connector market is expected to hit USD50.2 billion (representing a slight increase of 2.6% compared with 2013). The growth of the automotive connector market is attributed to: First, the intensified automotive electronization (especially PEVs and PHEVs) generates more demand for connectors. Second, Chinese and American automotive markets grow strongly, particularly luxury cars and SUVs featured with higher electronization degree and higher requirements on quality grow aggressively.

About Us

Browse Our Press Releases by Prnewswire: http://www.prnewswire.com/news/marketresearchreports.biz

Contact Us

Office: State Tower

90 Sate Street, Suite 700

Albany, NY 12207

United States

Tel: +1-518-618-1030

USA: Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz